7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013)


SUPL01 Opening Session
  Plenary Session
Venue: Session Room 1
Time: 30.06.2013, 19:45 - 20:45
Doors open at 19:00
A Gamelan performance by the University of Malaya Cultural Centre will begin at 19:15
Session recording provided by International AIDS Society
Session recording provided by International AIDS Society

19:45
SUPL0101
Welcome to IAS 2013
F. Barré-Sinoussi, France
A. Kamarulzaman, Malaysia

19:55
SUPL0102
Community welcome
A. Tan, Malaysia

20:05
SUPL0103
Welcome from the Government of Malaysia
Y. B. Datuk Seri Dr. S. Subramaniam, Minister of Health, Malaysia

20:15
SUPL0104
Musical Interlude, University of Malaya Cultural Centre

20:20
SUPL0105
Powerpoint
Keynote address
S. Deeks, United States

20:40
SUPL0106
Official opening of the conference
F. Barré-Sinoussi, France
A. Kamarulzaman, Malaysia

Powerpoints presentations
Keynote address - Steve Deeks



Rapporteur report

Track B report by Jürgen Rockstroh


In the opening ceremony Steve Deeks presented his vision on the end to AIDS in an enlightening lecture on the key unmet needs and challenges in moving forward HIV research. Clearly, the major unmet challenge and priority number one is to get HIV treatment to all in need. However, wherever treatment becomes available HIV becomes a chronic treatable disease. HIV as a chronic disease is characterized by low-level immune activation/immune dysfunction, subtle but cumulative treatment related toxicities, excess comorbidities, clinical aging and overburdened health care systems not designed for chronic care. Eventually only a cure will be able to address many if not all of these limitations of chronic antiretroviral therapy. Inflammation appears to be predictive of disease in HIV-infected individuals which will most become apparent late in life. Multiple therapeutic options are currently in development trying to prevent or reverse inflammation, multi-morbidity and “premature” aging including anti-inflammatory drugs,anti-coagulants, anti-fibrotic and anti-aging drugs. Can HIV cure address the remaining limitations of ART? Although the barriers are real, according to Deeks there are reasons to be optimistic. Research and clinical priorities in the era of complete viral suppression are to test and treat, reduce inflammation, insure healthy aging and provide chronic care until there is a successful cure strategy for all.




   

    The organizers reserve the right to amend the programme.